Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab

Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab

Treatment with rituximab (RTX) blunts SARS-CoV-2 vaccination-induced humoral response. We sought to identify predictors of a positive immunogenic response to the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD) treated with RTX (AIIRD-RTX). We analyzed 108 AI...

Full description

Bibliographic Details
Main Authors: Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman, Daphna Paran, David Levartovsky, Michael Zisapel, Ofir Elalouf, Ilana Kaufman, Adi Broyde, Ari Polachek, Joy Feld, Amir Haddad, Tal Gazitt, Muna Elias, Nizar Higazi, Fadi Kharouf, Sara Pel, Sharon Nevo, Ori Elkayam
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Vaccines
Subjects:
mRNA vaccine
COVID-19
SARS-CoV-2
rituximab
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/10/6/901

Internet

https://www.mdpi.com/2076-393X/10/6/901

Similar Items